CORRECTING and REPLACING — Neuralstem, Inc.

GERMANTOWN, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) — In a release issued yesterday by Neuralstem, Inc. (Nasdaq:CUR), please note the headline should be, “Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-566 in Ischemic Stroke,” rather than, “Neuralstem Announces Initiation of Phase 2 Clinical

Read More